Ultragenyx Pharmaceutical Inc.
RARE
$33.47
$0.100.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -180.41M | -114.95M | -151.08M | -133.39M | -133.52M |
| Total Depreciation and Amortization | 8.61M | 8.62M | 8.99M | 9.08M | 8.76M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.53M | 19.87M | 32.25M | 22.05M | 26.94M |
| Change in Net Operating Assets | 54.86M | -21.81M | -56.63M | 22.75M | 30.83M |
| Cash from Operations | -91.42M | -108.27M | -166.48M | -79.50M | -67.00M |
| Capital Expenditure | -1.28M | -2.46M | -1.32M | -654.00K | -1.62M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118.46M | 73.64M | 121.21M | 103.39M | -273.89M |
| Cash from Investing | 117.18M | 71.18M | 119.89M | 102.74M | -275.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00K | 83.65M | 157.00K | 3.19M | 4.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 7.00M |
| Cash from Financing | 2.00K | 83.65M | 157.00K | 3.19M | 11.17M |
| Foreign Exchange rate Adjustments | 294.00K | 2.91M | 1.45M | -2.47M | 1.28M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.06M | 49.47M | -44.98M | 23.95M | -330.05M |